For research use only
| Cat No. | ABC-X0202C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Host Cell | 293T |
| Source Organ | Kidney |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The Xpress™ Human LOXL4 Overexpression Cell Line (293T) supports cancer studies involving extracellular matrix remodeling and tumor microenvironments.
The LOXL4 293T Overexpression Cell Line is a genetically engineered model derived from human embryonic kidney 293T cells based on customers’ requirement. LOXL4 293T overexpression cell line is generated by stable integration of exogenous human LOXL4 into 293T host cells using our optimized transduction of lentiviral vectors. Overexpression clone is validated at gene level by qRT-PCR.
Target
The LOXL4 gene encodes lysyl oxidase-like 4, an enzyme involved in extracellular matrix remodeling and crosslinking of collagen and elastin. LOXL4 is implicated in tumor progression, metastasis, and hypoxia-induced signaling in various cancers, including hepatocellular carcinoma and breast cancer. Its dysregulation correlates with fibrotic disease and poor clinical prognosis. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0202C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Kidney |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | 293T |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The LOXL4 293T Overexpression Cell Line serves as a valuable tool to investigate LOXL4-mediated ECM remodeling, metastatic potential, and tumor microenvironment modulation. It supports drug screening targeting hypoxia-related fibrotic and neoplastic processes.